[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-metastases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,76,101,129,153,180,215,256,294,319,338,365,391,419,446,464,486],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100615328","a-feasibility-study-of-mass-based-response-drug-screening-to-guide-personalized-hyperthermic-intraperitoneal-chemotherapy-for-high-grade-appendiceal-and-colorectal-adenocarcinoma-with-peritoneal-metastasis-100615328",false,"NCT07291180","A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis","Inclusion Criteria:\n\n* Has histologically confirmed peritoneal metastases with primary diagnosis of AJCC 8th Edition Stage IV\n\n  1. Appendiceal adenocarcinoma (moderately\u002Fpoorly differentiated, and\u002For signet ring cell tumors)\n  2. Colorectal adenocarcinoma\n  3. Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary\n* Limited or no extraperitoneal metastases (any of the below)\n\n  a) Any extraperitoneal metastases must be limited, stable and treatable\n* Has adequate organ function, as described below; all screening laboratory tests should be performed within 30 days prior to the first HIPEC\n* Expected survival at the time of first HIPEC is greater than 3 months\n* Exhibits unresectable disease (bowel or mesenteric involvement) or PCI \\> 19\n\nDemographics\n\n* Adult patient at least 18 years of age at the time of signing informed consent and less than 81 years of age at the time of signing informed consent.\n* Has an ECOG performance status score of 0-2.\n\nMale Participants\n\n* A male participant must agree to use contraception (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.\n\nFemale Participants\n\n* A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence). Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nInformed Consent\n\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR.\n\nAlternative Eligibility\n\n* In addition to the criteria above, if a patient has undergone less than 8 rounds of chemotherapy at another institution (prior to initial diagnostic laparoscopy) and has not undergone radiation, ablative procedures, or cytoreductive surgery, then they are still eligible to enter the study at the second diagnostic laparoscopy step\n\nExclusion Criteria:\n\n* Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Has a known allergy to medications used in this study. Note: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.\n* Has hypoxia as defined by pulse oximeter reading \\\u003C92% at rest or requires intermittent or chronic supplemental oxygen.\n* No concurrent malignancy that may interfere with the study aims at the discretion of the investigator.\n\nNote: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n\n* Has known significant extraperitoneal metastasis.\n* Has creatine clearance \\\u003C60 mL\u002Fm\\^2 per the Cockcroft-Gault formula\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.\n* Has poorly controlled hypertension defined as SBP ≥150mmHg and\u002For DBP ≥90mmHg.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n* Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).\n* Has progressive disease following the first 3 months of systemic chemotherapy prior to HIPEC who is not in a stable condition to continue with the trial.\n\nPrior\u002FConcomitant Therapy\n\n* Has received radiation, ablative procedures, cytoreductive surgery, or systemic therapy including chemotherapy to treat metastatic disease within 3 months of initial laparoscopy.\n\nDiagnostic Assessments\n\n* Has an active infection requiring systemic therapy.\n* Has a known active TB\u002F COVID infection.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study intervention.\n* Has a known history of poorly controlled HIV infection despite anti-retroviral therapy.\n* Has a known history of HBV (defined as HBsAg reactive) or known active HCV (defined as HCV RNA \\[qualitative\\] is detected) infection that is poorly controlled.\n\nNote: Testing for HBV and HCV is only required if mandated by the local health authority.\n\nOther Exclusions\n\n* Inability to receive chemotherapy due to medical\u002Finsurance reasons.\n* Requires emergency surgery due to bleeding, perforation, or obstruction.\n* Has undergone previous iterative intraperitoneal therapy.\n* Has contraindication to chemotherapy of choice.","ALL","18 Years","81 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).",[26,27,28],"Appendiceal Cancer","Colorectal Adenocarcinoma","Peritoneal Metastases",[26,27,28,30],"Iterative Hyperthermic Intraperitoneal Chemotherapy (IHIPEC)","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":35},"2026-02-17",{"date":39,"type":20},"2027-12",{"name":41,"class":42},"Yale University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100639502","phase-2-mri-guided-adaptive-radiotherapy-for-limited-peritoneal-metastases-maracas-trial-100639502","NCT07593261","MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).","MARACAS: A Phase II Trial of MRI-guided Adaptive Stereotactic RAdiotherapy in oligometastatiC Patients With Peritoneal Spread.","MARACAS","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status 0-2\n* Life expectancy ≥6 months\n* Up to 5 MRI-visible peritoneal nodules\n* PCI ≤20\n* No prior radiotherapy in the same abdominal region within 6 months\n* Signed informed consent\n* History of prior CRS and\u002For HIPEC\n\nExclusion Criteria:\n\n* Diffuse peritoneal carcinomatosis\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial)\n* Significant comorbidities (such as: severe cardiac or coagulative disease, moderate or severe\n* restrictive\u002Fobsiructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.\n* Pregnancy or breastfeeding\n* MRI contraindications (e.g., pacemaker, severe claustrophobia)",{"count":53,"type":20},34,[55],"PHASE2","This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors. Eligible patients with up to 5 MRI-visible peritoneal lesions and PCI ≤20 will be treated with MRIgSBRT using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking.\n\nThe primary endpoint is radiologic response rate according to RECIST 1.1 criteria. Secondary endpoints include overall survival, progression-free survival, local control, chemotherapy-free survival, and treatment-related toxicity. The study aims to assess MRIgSBRT as a safe and non-invasive treatment option for selected patients with limited peritoneal metastatic disease.",[58,59,28],"Peritoneal Carcinomatosis","Oligometastatic Disease",[61,62,63,64,65],"MRI-guided radiotherapy","Stereotactic body radiotherapy","Peritoneal carcinomatosis","Peritoneal metastases","Online adaptive radiotherapy","NOT_YET_RECRUITING","2026-05-12",{"date":69,"type":35},"2026-05-18",{"date":71,"type":20},"2026-07",{"date":73,"type":20},"2032-07",{"name":75,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100544314","phase-2-the-application-of-pressured-intraperitoneal-aerosol-chemotherapy-pipac-for-peritoneal-surface-malignancies-100544314","NCT06367270","The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies","PIPAC","Inclusion Criteria:\n\n1. ≥18 years of old;\n2. WHO performance of status 0-1;\n3. Histologically or cytologically proven PM of a gastric, pancreatic or colorectal carcinoma;\n4. Treatment naïve patients as first-line treatment;\n5. Progression on or intolerance to first-line systemic chemotherapy as second-line treatment;\n6. No symptoms of gastrointestinal obstruction;\n7. No contraindications for the planned systemic therapy or laparoscopy;\n8. No previous PIPAC\u002FIP\u002FHIPEC;\n9. No other concurrent malignancies or any other malignancy within 6 months prior to enrolment;\n10. Able to give written informed consent.\n\nExclusion Criteria:\n\n1. A history of allergic reaction to platinum containing compounds or doxorubicin;\n2. Pregnant or breastfeeding;\n3. Any extra-peritoneal metastases;\n4. Renal impairment, defined as GFR less than 40 mL\u002Fmin;\n5. Impaired liver function defined as bilirubin over 1.5 × UNL;\n6. Inadequate haematological function\n\n   * Leucocyte \\\u003C 3.00 × 109\u002FL\n   * Absolute neutrophil counts \\\u003C 1.50 × 109\u002FL\n   * Platelet \\\u003C 100 × 109\u002FL",{"count":84,"type":20},60,[55],"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel minimally invasive drug delivery system for patients with peritoneal metastases (PM). It has been considered as a safe and feasible palliative treatment alternative proven by previous phase I studies. Currently available evidence on feasibility, efficacy and tolerability in Asian populations is limited. In this open-label, single-arm, monocentric clinical trial, investigators aim to evaluate the therapeutic efficacy and complications of PIPAC with oxaliplatin as an alternative on patients of unresectable colorectal cancer with PM and doxorubicin and cisplatin on patients of unresectable gastric and pancreatic cancers with PM. Alternative regimen can be considered multidisciplinary tumour board meeting. Patients will be recruited according to the inclusion criteria and treated for 3 cycles of PIPAC and concurrent systemic chemotherapy. The goal was to repeat PIPAC every 6-8 weeks for at least three procedures, and the delay of the systemic chemotherapy is 2 weeks before and after each PIPAC procedure. If PM was considered to become resectable during PIPAC, patients were discussed at the multidisciplinary tumour board for curative intent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The primary outcome is the clinical benefit rate (CBR), measured by an independent radiologist according to Response Evaluation Criteria In Solid Tumors (RECIST) and Peritoneal Cancer Index (PCI) assessed by laparoscopy and histopathological tumour response evaluated by pathologists blinded to clinical outcomes. Key secondary outcomes include the major and minor treatment-related adverse events according to the Common Terminology Criteria for Adverse Events (CTACE) up to 4 weeks after the treatment, Cytological tumour response of peritoneal lavage or ascites, treatment-related characteristics, hospital stay, progression-free survival, overall survival and readmission rate. The proposed study duration is 3 years from the start date and the estimated sample size is 51 according to centre capacity.",[28],[89,64,90,91],"Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC)","Oxaliplatin","Intraperitoneal chemotherapy","2026-04-29",{"date":94,"type":35},"2026-04-30",{"date":96,"type":35},"2023-09-01",{"date":98,"type":20},"2027-08-31",{"name":100,"class":42},"The University of Hong Kong",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100624589","phase-1-dual-administration-of-intraperitoneal-and-intravenous-trop2-directed-car-nk-with-tgf-beta-receptor-2-tgfbr2-knock-out-ko-therapy-for-colorectal-cancer-related-peritoneal-carcinomatosis-a-phase-12-trial-chip-crc-trial-100624589","NCT07411599","Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1\u002F2 Trial (\"Chip-CRC Trial\")","Eligibility Criteria\n\n* Subjects must be 18 years or older. Because no dosing or adverse event data are currently available on the use of IP\u002FIV TROP2 CAR\u002FIL-15 TGFBR2 KO NK Cell Therapy + Cetuximab in participants 3 liver metastases, \\>5 lung metastases, or \\>8 metastases combined between all extraperitoneal sites will not be included even in the setting of measurable peritoneal disease. If a participant has peritoneal-predominant disease with ≤ 8 total extraperitoneal metastases, they may be included at the discretion of the PI.\n* Subjects must be at least 4 weeks from their last dose of systemic cytotoxic chemotherapy at the time of their diagnostic laparoscopy (DL)\u002FIP catheter placement or 6 weeks if the chemotherapy regimen included Bevacizumab. Participants must be at least 4 weeks from their last dose of systemic cytotoxic chemotherapy at the time of their lymphodepleting (LD) chemotherapy.\n* Subjects must be willing to undergo DL and IP catheter placement along with scheduled peritoneal fluid\u002Fperipheral blood draws and biopsies.\n* Subjects must have adequate organ function as defined in the following table. Specimens must be collected within 10 days prior to the start of study treatment.\n* Participant s must have histologically confirmed microsatellite stable (MSS) CRC-related PM that is not amenable to curative resection (participant determined not to be a candidate for CRS +\u002F- HIPEC by surgical oncologist with expertise in peritoneal surface malignancies) and for which standard curative treatment is no longer effective (they have progressed through at least one line of standard systemic chemotherapy and\u002For are intolerant of systemic chemotherapy in the opinion of their primary medical oncologist). • MSS status must be confirmed either by immunohistochemistry (IHC) or polymerase chain reaction (PCR)-based genetic analysis. Participants with MSI-H tumors are ineligible. • Participant must have never undergone a prior HIPEC operation (CRS without HIPEC is OK) • Participant s with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participant s should be class 2B or better.\n* Women of childbearing potential (WOCBP): The effects of CAR NK therapy on the developing human fetus are unknown. For this reason and because lymphodepleting (LD) chemotherapy agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 4 months after completion of CAR NK therapy administration. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participant s, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following:\n* Postmenopausal (no menses in greater than or equal to 12 consecutive months). o History of hysterectomy or bilateral salpingo-oophorectomy.\n* Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n* History of bilateral tubal ligation or another surgical sterilization procedure.\n\nApproved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. See Appendix 1 for more details.\n\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of TROP2 CAR\u002FIL-15 TGFBR2 KO NK cells therapy administration.\n\nExclusion Criteria\n\n* Pregnant, breastfeeding, or expecting to conceive within the projected duration of the study, starting with screening visit through 4 months after last dose of trail treatment (TROP2 CAR\u002FIL-15 TGFBR2 KO NK cell therapy). If a WOCBP has a positive urine pregnancy test within 72 hours prior to administration of LD chemotherapy that cannot be confirmed as negative, a serum pregnancy test will be required.\n* Participants with BRAFV600E mutated tumors (determined by Next Generation Sequencing, NGS) will be excluded.\n* Has received systemic anti-cancer therapy within 4 weeks of their scheduled diagnostic laparoscopy (DL)\u002FIP catheter placement or 6 weeks if the regimen included Bevacizumab. Or has received systemic chemotherapy of any kind within 4 weeks prior to the time of their lymphodepleting (LD) chemotherapy.\n* Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy, alopecia, or other AEs may be deemed eligible at the discretion of the PI. If a participant received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n* Has received prior radiotherapy within 2 weeks of the start of study intervention (DL). Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout if permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.\n* Has received a live vaccine within 30 days prior to the initiation of LD chemotherapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus-Calmette-Guérin (BCG), and typhoid vaccines. Seasonal influenza and COVID vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.\n* Is currently receiving another investigational agent or has used an investigational device within 6 weeks prior to the first dose of study intervention. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 6 weeks after the last dose of the previous investigation agent.\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose LD.\n* High-volume extra-peritoneal visceral metastases to include but are not limited to, high volume (\\>3) liver metastases, high volume (\\>5) lung metastases, CNS metastases (any number) and\u002For carcinomatous meningitis, bone metastases (any number) will be excluded. Any participant s with \\>8 total metastases combined between all visceral extraperitoneal sites will also be excluded. Low volume liver (≤3) and\u002For lung (≤5) metastases that have been treated, are amendable to locoregional therapy, and are not an immediate threat to life may be included at the discretion of the PI if the total number of visceral extraperitoneal metastases remains ≤ 8. Individuals with nodal metastases and\u002For abdominal wall metastases similarly may be included at the discretion of the PI.\n* Active autoimmune disease that has required systemic treatment in the past 2 months (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.\n* History of interstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Serious active infection requiring intravenous systemic therapy.\n* Uncontrolled Human Immunodeficiency Virus (HIV) infection. Participants with HIV who have an undetectable viral load and a CD4 count of at least 400 cells\u002Fmm3 may participate.\n* Known Hepatitis B Virus (HBV) not on suppressive therapy or with detectable viral load on suppressive therapy. If undetectable viral load on suppressive therapy, OK to participate.\n* Known Hepatitis C Virus who has not been treated or cured, or who is currently being treatment with a detectable viral load. If cured or being treated with an undetectable viral load, OK to participate.\n* Known history of active Tuberculosis (TB).\n* History or current evidence of any condition, therapy, or laboratory abnormalities that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has had allogeneic tissue\u002Fsolid organ transplant.\n* Clinically significant cardiovascular disease within 12 months from the first dose of study intervention, including New York Heart Association (NYHA) Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular event, or cardiac arrhythmia associated with hemodynamic instability. Note: medically controlled arrhythmia would be permitted.\n* Prolonged QTcF interval to \\>480 ms.\n* Bleeding or thrombotic disorders or subjects at risk of severe hemorrhage. Subject with known deep vein thrombosis\u002Fpulmonary embolism that are under appropriate anticoagulation treatment are eligible.\n* Radiographic distribution of disease that in the investigator's opinion would impart excessive risk to participation to this protocol.\n* Active peritonitis or diverticulitis.\n* Medical or surgical history that in the treating physician's opinion would make the subject not a suitable candidate for intraperitoneal therapy. Examples would include surgically documented extensive intraperitoneal adhesions, prior HIPEC operation, or large volume ascites.\n* History of severe hypersensitivity reaction with biologic therapies (e.g. monoclonal antibodies).",{"count":108,"type":20},28,[110,55],"PHASE1","To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.",[113,28,114],"Colorectal Cancer","Carcinomatosis",[116,117,118,119],"Trop2","CAR-NK","Phase 1\u002F2","TGfBR2","2026-04-22",{"date":122,"type":35},"2026-04-23",{"date":124,"type":35},"2026-04-20",{"date":126,"type":20},"2030-11-15",{"name":128,"class":42},"M.D. Anderson Cancer Center",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":43},"100629727","impact-of-an-omega-3-enriched-oral-nutritional-supplement-on-improving-surgical-outcomes-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-100629727","NCT07478432","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery: A Pilot, Prospective, Randomized, Double-Blind, Controlled Study","OMNI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of peritoneal carcinomatosis from a non-gynecological primary neoplasm\n* Patients who must undergo cytoreductive surgery and HIPEC\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients with an enterocutaneous fistula\n* Patients with known food allergies\n* Age \\\u003C 18 years\n* Patients with severe organ damage (e.g., kidney failure, liver failure)\n* Refusal to sign the informed consent form",{"count":108,"type":20},[23],"The OMNI study is a clinical trial investigating whether a nutritional supplement with added Omega-3 fatty acids can improve surgical outcomes for patients with peritoneal carcinomatosis. Peritoneal carcinomatosis is a type of cancer that affects the abdominal lining and often requires complex and extensive surgery called cytoreductive surgery (CRS). This procedure is associated with a high risk of postoperative complications, such as infections and long hospital stays. Omega-3 fatty acids are known for their anti-inflammatory and immune-modulating properties.\n\nThe study's main goal is to see if a 21-day regimen of a pre-operative Omega-3 enriched oral nutritional supplement (ONS) can reduce postoperative complications, as measured by the Clavien-Dindo classification.\n\nWho can participate?\n\nThe study is recruiting patients over 18 years old who have been diagnosed with non-gynecological peritoneal carcinomatosis and are scheduled to undergo cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy).\n\nWhat does participating involve?\n\nUpon joining the study, participants will be randomly assigned to one of two groups:\n\n* Intervention Group: Participants will receive an Omega-3 enriched nutritional supplement called Fortimel Forticare.\n* Control Group: Participants will receive a standard nutritional supplement called Fortimel Compact Protein.\n\nBoth groups will be asked to consume two bottles of their assigned supplement per day for 21 days before the scheduled surgery.\n\nWhat will be measured?\n\nThroughout the study, the investigators will perform various assessments to monitor participant health and recovery:\n\n* Before and after surgery: The investigators will take body measurements, conduct a bioimpedance analysis (BIA) to check body composition, and perform a Hand Grip test to measure muscle strength. The investigators will also collect blood and stool samples.\n* During surgery: The investigators will collect tissue samples to study the tumor environment.\n* After surgery: The investigators will track patient recovery, including the length of the hospital stay and any complications that may occur. The investigators will also continue to monitor certain markers in the patients' blood.\n\nThe study is expected to enroll a total of 28 patients.",[141,28,142,143],"Peritoneal Carcinosis","HIPEC","Cytoreductive Surgery","2026-03-13",{"date":146,"type":35},"2026-03-17",{"date":148,"type":20},"2026-04",{"date":150,"type":20},"2028-10",{"name":152,"class":42},"Catholic University of the Sacred Heart",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100556015","phase-2-systemic-application-of-cadonilimab-lm-302-and-s-1-combined-with-intraperitoneal-infusion-of-paclitaxel-for-the-treatment-of-claudin-182-positive-gastric-cancer-with-peritoneal-metastasis-100556015","NCT06519591","Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;\n2. Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy, and without gastric outflow tract obstruction and intestinal obstruction; Written (signed) informed consent;\n3. Claudin 18.2 positive (≥ 25%, and the proportion of positive cells greater than 50% of the cases accounted for not less than 70%);\n4. Age ≥ 18 years at registration;\n5. Eastern Cooperative Oncology Group (ECOG) score ≤ 1;\n6. Expected life expectancy \\> 3 months;\n7. Adequate bone marrow, liver, and renal functions.\n\nExclusion Criteria:\n\n1. Confirmed of evidence of distant metastasis other than peritoneal metastasis (e.g.liver metastasis, lung metastasis, para-aortic lymph node metastasis, etc.);\n2. During pregnancy, within 28 days of post parturition, or during lactation;\n3. Previously received immunotherapy such as PD-1\u002FPD-L1 and CTLA-4 or targeted therapy such as Claudin 18.2.\n4. Synchronous or metachronous (within 5 years) malignancies.\n5. Severe mental disease, uncontrolled epilepsy, or central nervous system disease;\n6. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months;\n7. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome may affect S-1 absorbers;\n8. Known peripheral neuropathy (\\> NCI-CTC AE 1). However, patients with only disappearance of deep tendon reflex (DTR) need not be excluded;\n9. Patients on steroid or immunosuppressant treatment after organ transplant;\n10. Patients with severe uncontrolled recurrent infections or other severe uncontrolled concomitant disease;\n11. Moderate or severe renal damage \\[creatinine clearance ≤ 50 ml\u002Fmin\\], or serum creatinine \\> upper limit of normal (ULN), 115 μmol\u002FL;\n12. Known dihydropyrimidine dehydrogenase (DPD) deficiency;\n13. Anaphylaxis to paclitaxel or any research drug ingredient.\n14. Active autoimmune disease or history of refractory autoimmune disease;\n15. Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected;\n16. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥10 copies\u002Fml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);\n17. Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg\u002Fday of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents;\n18. Uncontrolled arrhythmia and myocardial infarction within 12 months before admission or active tuberculosis.",{"count":160,"type":20},40,[55],"In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.",[164,28],"Gastric Cancer Stage IV",[166,167,168,169,170],"Gastric cancer","Peritoneal metastasis","Cadonilimab","Claudin 18.2","Paclitaxel","2026-02-13",{"date":173,"type":35},"2026-02-18",{"date":175,"type":35},"2025-02-25",{"date":177,"type":20},"2026-12",{"name":179,"class":42},"Ruijin Hospital",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":188,"enrollmentInfo":189,"targetDuration":191,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100497317","on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life-100497317","NCT05755672","On-treatment Biomarkers in Metastatic Colorectal Cancer for Life","On-treatment Biomarkers in Metastatic Colorectal Cancer for Life: The On-CALL Study","On-CALL","Inclusion Criteria:\n\n* Clinical diagnosis of synchronous metastatic colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital\n\nExclusion Criteria:\n\n* Not accepting the study inclusion terms (informed consent not obtained)\n* Age below or above the age limit","110 Years",{"count":190,"type":20},100,"10 Years","OBSERVATIONAL","By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.\n\nThe On-CALL study is a prospective, single-arm observational study. All patients diagnosed with synchronous mCRC treated with curative intent at Skåne University Hospital will be invited to participate. Clinical and histopathological data will be compiled at study entry. An individual tissue microarray block with samples from resected primary tumours and metastases representing the full extent of the tumour spread will be constructed for each patient. Blood samples will be drawn for biomarker analyses at multiple time points prior to, during and after systemic treatment. DNA sequencing of tumour tissue and circulating tumour DNA (ctDNA) will be performed to define the spatial clonal landscape in primary tumours and metastases, as well as over time.",[195,196,28,197,198],"Metastatic Colorectal Cancer","Chemotherapy Effect","Liver Metastasis Colon Cancer","Lung Metastases",[200,201,202,203,204],"Metastatic colorectal cancer","Chemotherapy","Targeted therapy","Tumor heterogeneity","Tumor evolution","2025-07-14",{"date":207,"type":35},"2025-07-17",{"date":209,"type":35},"2023-03-01",{"date":211,"type":20},"2033-03",{"name":213,"class":42},"Region Skane",2,{"id":216,"slug":4,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":232,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":43},"100460602","NCT05277766","Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer","Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study","PIPAC-NAL-IRI","Inclusion Criteria:\n\n* Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis\n* Estimated life expectancy \\> 6 months; \\> 3 months if primary cancer is pancreatic\n* Age ≥ 18 years\n* Adequate performance status (Karnofsky index \\> 60% and WHO performance status \\\u003C 2)\n* Written informed consent obtained prior any act of the research\n\nExclusion Criteria:\n\n* Concomitant systemic (IV) treatment with irinotecan (either as monotherapy or as part of a combination regimen such as FOLFIRI, CAPIRI, or FOLFOXIRI)\n* Pregnancy or breastfeeding during the clinical study\n* Patients of childbearing age unable or unwilling to provide effective contraception during the study and until the end of relevant exposure (extended by 30 days (female participants) or 120 days (male participants) since the IMP is genotoxic).\n* Known allergy or intolerance to irinotecan\n* Significant amount of ascites detectable (exceeding 3l in volume)\n* Intestinal or urinary tract obstruction\n* Extensive hepatic and\u002For extra-abdominal metastatic disease\n* Impaired renal function (serum creatinine \\> 1.5 mg\u002Fdl or calculated GFR (CKD-EPI) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Impaired liver function (serum total bilirubin \\> 1.5 mg\u002Fdl, except for known Gilbert's disease)\n* Platelet count \\\u003C 100.000\u002Fµl\n* Hemoglobin \\\u003C 9g\u002Fdl\n* Neutrophil granulocytes \\\u003C 1.500\u002Fml\n* Patients known to use:\n\n  * CYP3A4 inducers (rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St John's wort)\n  * inhibitors of CYP3A4 (clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (atazanavir, gemfibrozil, indinavir, regorafenib)",{"count":223,"type":20},45,[110],"The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.",[58,28,113,227,228,229,230,231],"Small Bowel Cancer","Appendix Cancer","Gastric Cancer","Pancreatic Cancer","Bile Duct Cancer",[81,233,63,234,235,236,237,238,239,240,241,242,243,244,245,246,64],"Nal-IRI","dose-finding study","pharmacokinetics","pharmacodynamics","safety and efficacy","Onivyde","Primary gastrointestinal cancer","Colorectal cancer","Small bowel cancer","Appendix cancer","Stomach cancer","Pancreatic cancer","Cholangiocarcinoma","dose-escalation study","2025-06-26",{"date":249,"type":35},"2025-07-01",{"date":251,"type":35},"2022-11-21",{"date":253,"type":20},"2027-04",{"name":255,"class":42},"University Hospital, Ghent",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":279,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":43},"100593065","phase-1-intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors-100593065","NCT07001592","Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors","A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors","RIOT3","Inclusion Criteria:\n\n1. Males or females age, 18 to \\\u003C 70 years at the time of consent\n2. Histologically confirmed metastases from gastrointestinal tumors with molecular determinants for MSI and KRAS.\n3. For microsatellite stable (MSS) tumors, subjects must have failed (or be ineligible for) standard 1st and 2nd line chemotherapy. For microsatellite instability-high (MSI-H) tumors, subjects must also have failed (or be ineligible for) systemic immunotherapy.\n4. Karnofsky Performance Status (KPS) of \\> 70\n5. Anticipated survival of at least 12 weeks.\n6. Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures (subject or subject's legally authorized representative (LAR) must have the ability to understand and willingness to sign a written informed consent).\n7. Adequate bone marrow function: WBC \\> 2,000 and \\\u003C50,000 cells\u002Fmm3, ANC \\> 1,000 cells\u002Fmm3, hemoglobin \\>8 g\u002FdL, and platelet count \\>100,000 cells\u002Fmm3.\n8. Adequate renal function: serum creatinine level ≤ 2xULN\n9. Adequate liver function: Serum bilirubin \\\u003C 1.5 x ULN\n10. Acceptable coagulation status: INR \\\u003C ULN +15%. All patients must be able to suspend anticoagulant therapy for study specific biopsies and intra-tumoral injection.\n11. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have negative serum or urine pregnancy test.\n12. If sexually active, to prevent pregnancy and to prevent the spread of virus, subject must use an acceptable method of contraception as well as barrier contraception from screening through 6 weeks following study treatment with vvDD-hIL-2-RG-1.\n13. Subjects must be willing to comply with all study procedures, requirements, adhere to post-treatment care instructions and follow-up examinations.\n14. Have measurable disease based on RECIST 1.1 criteria.\n15. Have at least one tumor at least 1 cm in diameter amenable to safe intra-tumoral injection.\n\nExclusion Criteria:\n\n1. Pregnant or nursing an infant.\n2. Systemic corticosteroid or other immunosuppressive medication use within 2 weeks of the study treatment.\n3. Significant immunodeficiency (e.g. due to underlying illness and\u002For medication) in subject or household contacts (must be able to avoid household contact with immunodeficient person for 3 weeks).\n4. Clinically significant active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for investigational new drug treatment, per investigator discretion.\n5. Active eczema or psoriasis or other inflammatory skin conditions\n6. Unstable cardiac disease which includes but is not limited to any of the following within 6 months prior to study entry: myocardial infarction (MI), unstable angina, congestive heart failure, myocarditis, ventricular arrhythmias diagnosed and requiring medication.\n\n   * New York Heart Association functional class III-IV heart failure on active treatment\n   * Pulse oximetry of \\\u003C 90% in room air at rest\n7. Subjects who have received radiation, chemotherapy or other potentially immunosuppressive therapy within 2 weeks prior to study screening and within 4 weeks prior to anticipated vvDD-hIL-2-RG-1 treatment.\n8. Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination.\n9. Subjects who, in the opinion of the Investigator, have a medical condition that would subject the subject to prohibitive risk by participation in this study, or who may be unable to safely complete the required tumor biopsies.\n10. Subjects with household contacts who are children \\\u003C 5 years old, have active eczema, psoriasis or other inflammatory skin conditions or have a significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus) and\u002For medication (e.g. systemic corticosteroids) will be excluded unless alternate living arrangements can be made during the subject's active dosing period and for three weeks following the study medication.\n11. Vaccination with a live virus in the previous 60 days prior to Day 0.\n12. Inability or unwillingness to give informed consent.\n13. Is unable or unwilling to comply with protocol follow-up requirements. -","69 Years",{"count":5,"type":20},[110],"This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each level.\n\nvvDD-hIL2 is a genetically modified vaccinia virus, derived from the virus previously used for smallpox vaccination. The modification is intended to target and destroy tumors while minimizing harm to healthy tissues by stimulating the body's immune response.\n\nParticipants will receive an injection of vvDD-hIL2 directly into their abdominal tumors at AHN West Penn. The study team will monitor for side effects and assess tumor response to the treatment.\n\nActive participation will last up to two months, involving seven clinic visits and approximately four lab visits at AHN West Penn Hospital. Visits will include standard of care procedures as well as study-specific tests and exams. Most visits will last one to two hours, with some extending to two to three hours. The drug administration day will require a twelve-hour visit.\n\nEffectiveness and side effects will be evaluated through blood draws, oral swabs, urinalysis and tissue biopsies. Tissue samples will be used for genomic analysis and stored for potential future research. Data collected may also be used for future research purposes.\n\nPrevious human trials of vvDD-hIL2 have reported side effects such as pain, rash or inflammation at the injection site, low-grade fevers, flu-like symptoms, and fatigue. There is a rare risk of rash transmission to close contacts with skin openings, and information on limiting contact and managing rash development will be provided.",[269,270,271,272,273,274,275,276,277,28,278,229],"Gastric Neoplasms","Esophageal Cancer","Liver Cancer","Liver Metastasis","MSS-CRC","MSS","Gastric Adenocarcinoma","Peritoneal Cancer","Peritoneal Carcinoma","MSI-H",[280,281,282,283,284],"Oncolytic virus","vaccinia","immunotherapy","intra-tumoral","intra-peritoneal","2025-06-02",{"date":287,"type":35},"2025-06-03",{"date":289,"type":35},"2025-05-06",{"date":291,"type":20},"2028-05",{"name":293,"class":42},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":318},"100428630","phase-3-efficacy-of-hyperthermic-intraperitoneal-chemotherapy-100428630","NCT04861558","Efficacy of Hyperthermic Intraperitoneal Chemotherapy","EFFIPEC - Efficacy of Hyperthermic Intraperitoneal Chemotherapy, Single-arm Phase I Study, Followed by an Open-label, Randomized, Controlled Registry-based Phase III Trial","EFFIPEC","Inclusion criteria:\n\n1. Provision of written informed consent prior to any study specific procedures.\n2. ECOG Performance Status Score 0,1 or 2 alternatively Karnofsky 60-100\n3. Adequate kidney, liver, bone marrow function according to laboratory tests\n4. For females of childbearing potential, a negative pregnancy test must be documented\n5. ≥ 18 years old and ≤78 years old\n6. Colorectal cancer with peritoneal metastases +\u002F- liver metastases (maximum 3)\n7. Concomitant resectable pulmonary metastases are allowed\n8. All patients deemed eligible for CRS and HIPEC according to clinical routine management during a HIPEC multidisciplinary board at each respective hospital can be included.\n\nExclusion criteria:\n\n1. Previous severe toxicity\u002Fallergic reactions to systemic chemotherapy agents oxaliplatin or irinotecan or 5-fluorouracil\n2. Unable to tolerate intensified HIPEC treatment due to comorbidity\n3. Metastasis other than peritoneum or liver or lung\n4. Complex liver-perenchymal sparing surgery or hemihepatectomy procedures are to be excluded.\n5. Previous CRS or HIPEC\n6. Pregnant or lactating (nursing) women\n7. Active infections requiring antibiotics\n8. Active liver disease with positive serology for active hepatitis B, C, or known HIV\n9. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to and up to 4 weeks after study treatment\n10. Incomplete cytoreduction defined as completeness of cytoreduction score 2-3\n11. Histopathology of other origin than colorectal cancer","79 Years",{"count":304,"type":20},213,[306],"PHASE3","A dose titration study and a combined superiority registry-based open-label randomized control trial is planned to answer the trial objectives. The study will be registry-based to allow simpler and more comprehensive follow-up. Patients with colorectal cancer will be treated with cytoreductive surgery (CRS) together with either standard oxaliplatin HIPEC (the control for the efficacy study) or oxaliplatin\u002Firinotecan HIPEC in combination with 5-FU 24-hour EPIC. The 5-FU will be administered postoperatively when the abdomen is completely sutured. The drug is divided equally into 2 injections of 200 ml each and injected through two abdominal drains that are clamped for 16 hours.\n\nFor dose escalation, the titration groups (á 3 or 6 patients) are followed for 30 days postoperatively after which the Data Monitoring Committee (DMC) will determine whether or not to increase the 5-FU dose for the following group of patients.\n\nTo study efficacy, randomization is performed intraoperatively. The patient is followed up postoperatively for a total of 3 years for the secondary endpoints which may be extended by the study committee to 5 years. Since the trial is registry based, the long-term follow-up does not require separate eCRF evaluations. These evaluations can be automatically retrieved from the registry - both recurrence data, quality of life, and morbidity data. Some specific eCRF evaluations will be integrated as a separate study part of the HIPEC registry, such as inclusion\u002Fexclusion criteria and adverse event reporting (including SUSAR reporting).",[113,28],"2025-05-26",{"date":311,"type":35},"2025-05-30",{"date":313,"type":35},"2021-05-01",{"date":315,"type":20},"2029-12",{"name":317,"class":42},"Uppsala University",5,{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":43},"100585512","a-prospective-multicentre-clinical-study-of-dynamic-monitoring-of-plasma-ctdna-methylation-markers-to-predict-recurrence-of-colorectal-cancer-after-complete-resection-of-peritoneal-metastases-100585512","NCT06903325","A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases","Inclusion Criteria:\n\n-1. No gender limit, age greater than 18 years old; 2, ECOG score ≤1; 3. Life expectancy ≥2 years; 4. Colorectal adenocarcinoma\u002Fmucinous adenocarcinoma\u002Fsignet ring cell carcinoma confirmed by histopathology; 5, preoperative PCI score ≤20, peritoneal tumor cytoreductive surgery (CRS), surgery to achieve R0\u002F1 resection; 6. Be able to understand the situation of this study and sign the informed consent.\n\n7\\. The primary colorectal cancer has undergone R0 resection, and there is no extraperitoneal metastasis (except ovary).\n\nExclusion Criteria:\n\n* 1\\. Combined with primary malignant tumors of other organs (current or within the past 5 years) (excluding patients with skin basal cell carcinoma and cervical carcinoma in situ undergoing radical treatment); 2. Severe mental illness or drug abuse; 3, severe heart, lung, vascular disease can not tolerate surgery; 4. Pregnant or lactating women.",{"count":326,"type":20},50,"The goal of this clinical trial is to explore the predictive effect of postoperative plasma ctDNA methylation status on postoperative recurrence free survival (RFS) of colorectal cancer patients with peritoneal metastasis after R0\u002FR1 resection. The main questions it aims to answer are:\n\nPreoperative and postoperative plasma ctDNA methylation detection (ColonAiQ) was performed in patients with peritoneal metastasis from colorectal cancer who underwent R0\u002FR1 resection. Clinical information of patients was collected to explore the predictive effect of postoperative plasma ctDNA methylation status on postoperative recurrence free survival (RFS) of colorectal cancer patients with peritoneal metastasis.\n\nParticipants will:\n\nThe patients were followed up according to the normal review procedure of the hospital and the NCCN guidelines until at least 24 months after surgery. The review content included CT\u002FMRI imaging evaluation and blood CEA (every 3 months). Whole-blood samples were obtained for timely plasma separation and ctDNA extraction at 1 month after surgery (before the start of postoperative chemotherapy) and every 3 months through 24 months after surgery. One blood sample was obtained when tumor recurrence was first detected on imaging.\n\nDetection of methylation in tissue and plasma samples\n\n1. GutSeer methylation NGS was performed on peritoneal metastatic cancer tissues and paired normal peritoneal tissues.\n2. ctDNA GutSeer methylation NGS was performed on plasma samples before surgery, 1 month after surgery, 24 months after surgery, and when tumor recurrence was first detected by imaging examination.\n3. ctDNA methylation PCR (ColonAiQ) was performed on plasma samples before surgery, 1 month after surgery, every 3 months to 24 months after surgery, and when tumor recurrence was first detected by imaging examination.",[113,28],"2025-03-24",{"date":331,"type":35},"2025-03-30",{"date":333,"type":35},"2023-10-01",{"date":335,"type":20},"2027-10-31",{"name":337,"class":42},"Fudan University",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":318},"100538765","phase-2-the-efficacy-of-pipac-and-minimally-invasive-radical-resection-in-high-risk-gastric-cancer-patients-100538765","NCT06295094","The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.","The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study","EPICURE","Inclusion criteria\n\n* Gastric or Gastroesophageal junction Siewert type III adenocarcinomas\n* Clinical T3-4a-stages\n\n  1. Any differentiation grade\n  2. Any histological subtype\n* Clinical T2-stage\n\n  a. If poorly differentiated or of the poorly cohesive histological subtype, with or without the presence of signet-ring cells\n* Any clinical T-stage with positivity for malignant cells on abdominal lavage cytology, which is converted to cytology negative in response to neoadjuvant chemotherapy.\n* Any clinical nodal-stage\n* clinical M0-stage (positive abdominal wash cytology, which is converted to cytology negative in response to neoadjuvant therapy, is permitted)\n* Performance status Eastern Cooperative Oncology Group (ECOG) 0-1\n* Age 18 - 80 years\n* Undergoing robotic or laparoscopic D2 gastrectomy\n* Able and willing to provide written informed consent and to comply with the clinical study protocol\n* Fertile women must have a negative pregnancy test at the time of inclusion and must use adequate contraception.\n\nExclusion criteria\n\n* Previous allergic reaction to cisplatin, doxorubicin or other platinum-containing compounds.\n* Renal impairment, defined as glomerular filtration rate (GFR) \\\u003C 40 ml\u002Fmin (Cockcroft-Gault Equation).\n* Myocardial insufficiency, defined as New York Heart Association (NYHA) class 3-4.\n* An impaired liver function, defined as bilirubin ≥ 1.5 x upper normal limit (UNL).\n* An inadequate haematological function, defined as absolute neutrophil count (ANC) \\\u003C1.5 x 109\u002Fl and platelets \\\u003C100 x 109\u002Fl.\n* Any other condition or therapy which, in the investigator's opinion, may pose a risk to the patient or interfere with the study objectives.","80 Years",{"count":348,"type":20},264,[55],"The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.",[229,352,28,353],"Chemotherapy, Adjuvant","Minimally Invasive Surgical Procedures",[81,166,355],"Minimally invasive gastrectomy","2024-03-05",{"date":358,"type":35},"2024-03-06",{"date":360,"type":20},"2024-09",{"date":362,"type":20},"2028-01",{"name":364,"class":42},"Odense University Hospital",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":4},"100532493","phase-2-hipec-combined-with-sox-and-sintilimab-in-the-treatment-of-advanced-gastric-cancer-with-peritoneal-metastasis-100532493","NCT06213519","HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis","The Efficacy and Safety of Hyperthermic Intraperitoneal Chemotherapy （HIPEC）Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis: A Prospective, Single-arm, Phase II Clinical Study","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Unresectable gastric\u002Fgastroesophageal junction adenocarcinoma diagnosed with peritoneal metastasis through laparoscopic exploration and pathological or cytological examination;\n3. No previous antitumor treatment.\n4. Agree to provide blood\u002Ftissue specimens.\n5. The expected survival is more than 3 months.\n6. ECOG PS≤1.\n7. Adequate organ function including the following:\n\n   1. Total bilirubin ≤1.5 times the upper limit of normal (ULN);\n   2. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3×ULN;\n   3. Alkaline phosphatase≤2.5×ULN (if the tumor invaded the liver, ≤3×ULN);\n   4. Serum creatinine≤1.5×ULN;\n   5. Serum amylase and lipase≤1.5×ULN;\n   6. International standardized ratio (INR)\u002Fpartial thromboplastin time (PTT)≤1.5×ULN;\n   7. Platelet count ≥ 75,000 \u002Fmm3;\n   8. Hemoglobin (Hb) ≥ 9 g\u002FdL;\n   9. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3;\n8. Strict contraception.\n9. Patients must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.\n\nExclusion Criteria:\n\n1. Undergoing other drug clinical trials or having participated in any drug clinical trials one month before enrollment.\n2. Active autoimmune disease or history of refractory autoimmune disease.\n3. Receiving corticosteroids (\\> 10mg\u002Fd prednisone or equivalent dose of steroids) or other systematic immunosuppression therapies within 14 days before enrollment, excluding the following therapies: steroid hormone replacement therapy (≤10mg\u002Fd); local steroid therapy; and short-term, prophylactic steroid therapy for preventing allergies or nausea and vomiting.\n4. Active or clinically significant cardiac disease:\n\n   1. Congestive heart failure \\> New York Heart Association (NYHA) class 2;\n   2. Active coronary artery disease;\n   3. Arrhythmias requiring treatment other than β-blockers or digoxin;\n   4. Unstable angina (with angina symptoms at rest), new angina within 3 months before enrollment, or new myocardial infarction within 6 months before enrollment\n5. Gastrointestinal perforation, obstruction, or uncontrollable diarrhea in the 6 months prior to enrollment;\n6. Other tumors that have not been treated or exist at the same time, except carcinoma in situ of the cervix, treated basal cell carcinoma or superficial bladder tumor. If the tumor was cured and no evidence of disease was found for more than 3 years, the patient can be enrolled. All other tumors must be treated at least 3 years before enrollment.\n7. Patients with pheochromocytoma.\n8. Patients with a history of HIV infection or active hepatitis B\u002FC.\n9. Ongoing \\> level 2 infection.\n10. Symptomatic brain metastasis or meningioma.\n11. Unhealed wounds, ulcers or fractures.\n12. Renal failure patients requiring blood or peritoneal dialysis.\n13. Epileptic that needs medication.\n14. History of organ transplantation (including corneal transplantation).\n15. Allergic to research drugs or similar drugs, or suspected allergies.\n16. Pregnant or lactating women.\n17. Medical, psychological or social conditions can affect the recruitment of patients and evaluation of study results.\n18. Other antitumor therapy (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than investigator drugs. Palliative external irradiation for non-target lesions is allowed.\n19. Previously used similar chemotherapy drugs or immune checkpoint inhibitors;\n20. Major surgery 4 weeks before recruitment, open biopsy or major trauma surgery (excluding biliary stents, or percutaneous biliary drainage).\n21. Treatment with antitumor Chinese herbal medicine.\n22. Vaccination history 4 weeks prior to enrollment\n23. The investigator believes that patients who are not suitable for the study.","75 Years",{"count":374,"type":20},69,[55],"The prognosis of patients with peritoneal metastasis from gastric cancer is extremely poor. Although chemotherapy combined with immunotherapy has achieved promising efficacy in the first-line treatment of advanced gastric cancer, patients with peritoneal metastasis benefit less from this regimen. Hyperthermic intraperitoneal chemotherapy (HIPEC) represents a novel treatment option, which maintains the high concentration of drugs in the abdominal cavity, and improve the anti-tumor efficacy of chemotherapy drugs through the thermo-thermal effect. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy combined with sintilimab in the first-line treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma with peritoneal metastasis.",[28,229],[379,380,142,381],"gastric cancer","peritoneal metastasis","first-line","2024-01-18",{"date":384,"type":35},"2024-01-19",{"date":386,"type":20},"2024-02-20",{"date":388,"type":20},"2027-06-30",{"name":390,"class":42},"Sichuan University",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":43},"100463753","phase-2-neoadjuvant-systemic-and-peritoneal-chemotherapy-for-advanced-gastric-cancer-100463753","NCT05318794","Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer","Neoadjuvant Systemic and Peritoneal Chemotherapy for Regionally Advanced Gastric Cancer With Minimal Peritoneal Disease","SPECTRA","Inclusion Criteria:\n\n* Gastric adenocarcinoma (Tx, Nx) 1,2,3\n* Peritoneal cytology +ve or PCI ≤ 3\n* No solid organ metastasis 2\n* HER2 -ve\n* Male\u002Ffemale\n* Treatment naïve\n* BMI ≥ 18.5 kg\u002Fm2 or ≤ 40 kg\u002Fm2\n* WHO performance status ≤ 1\n* Dysphagia score ≤ 2\n* Informed written consent\n\nExclusion Criteria:\n\n* PCI ≥ 4\n* Solid organ metastasis\n* Positive lymph node disease beyond field of D2 lymphadenectomy\n* Peritoneal adhesions precluding complete laparoscopy\n* Ascites (greater than trace amount)\n* Malignant pleural effusion\n* Mechanical bowel obstruction (with the exception of gastric outlet obstruction)\n* HER2 +ve\n* Patients eligible for immunotherapy\n* Uncontrolled co-morbidity\n* single\u002Fmultiple organ failure\n* BMI \\\u003C 18.5 kg\u002Fm2 or \\> 40 kg\u002Fm2\n* WHO performance status \\> 1\n* Dysphagia score \\> 2\n* Contraindication to chemotherapy\n* Pregnancy or breastfeeding\n* Haemoglobin \\\u003C90 g\u002FdL uncorrected with blood transfusion",{"count":19,"type":20},[55],"Data demonstrating the efficacy of PIPAC in patients with regionally advanced gastric cancer with positive peritoneal cytology and\u002For minimal peritoneal disease is limited due to the relatively recent development of this technique and its historical preferential use in palliative patients with disseminated peritoneal metastasis.\n\nExisting data suggest PIPAC administered every six weeks in conjunction with standard treatment may work as an adjunct to conventional systemic neoadjuvant chemotherapy. PIPAC protocols have been established both for gastric cancer as well as other intra-abdominal malignancies and have a good safety profile.\n\nGiven these promising findings, a study protocol is proposed herein to further investigate PIPAC for the treatment of a highly selected group of patients with regionally advanced gastric cancer (positive peritoneal cytology and\u002For minimal peritoneal disease).",[229,28,196],[404,81,405,406,407,408,409],"Pressurised intraperitoneal aerosol chemotherapy","Neoadjuvant therapy","Gastrectomy","Curative","Doxorubicin","Cisplatin","2023-09-12",{"date":412,"type":35},"2023-09-13",{"date":414,"type":20},"2023-11",{"date":416,"type":20},"2030-07",{"name":418,"class":42},"Imperial College London",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":445},"100494753","prediction-of-peritoneal-metastasis-for-gastric-cancer-based-on-radiomics-100494753","NCT05722275","Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics","Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics: a Multi-center Prospective Study","Inclusion Criteria:\n\n* (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and\u002For endoscopic ultrasound;\n* (2) with both enhanced CT and laparoscopy;\n* (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);\n* (4) without other evidence of distant metastasis, and no stage IV features on CT.\n\nExclusion Criteria:\n\n* (1) previous abdominal surgery;\n* (2) previous abdominal malignancies or inflammatory diseases;\n* (3) time intervals between CT and laparoscopy longer than 2 weeks;\n* (4) CT image artifacts that undermine peritoneal lesion assessment.",{"count":427,"type":20},400,"Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.",[229,28],[431,432,229,28,433,434],"Artificial Intelligence","Classification","Computed Tomography","Radiomics","2023-02-12",{"date":437,"type":35},"2023-02-14",{"date":439,"type":35},"2023-01-01",{"date":441,"type":20},"2028-12-31",{"name":443,"class":444},"Chinese Academy of Sciences","OTHER_GOV",13,{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":372,"enrollmentInfo":452,"targetDuration":4,"studyType":21,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":462,"locationsCount":4},"100462383","phase-2-hipec-combined-gastrectomy-in-patients-with-advanced-gastric-cancer-received-neoadjuvant-chemotherapy-100462383","NCT05300945","HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* histologically proven adenocarcinoma of stomach\n* stage cT3-4N+M0\n* no involvement of esophagus \\> 3 cm\n* ECOG (Eastern Cooperative Oncology Group) : 0\\~1\n* no previous chemotherapy or radiotherapy for any malignancy\n* no previous surgery for GC excluding endoscopic mucosal resection or endoscopic submucosal dissection\n* Signed the Informed Consent Form\n\nExclusion Criteria:\n\n* Serious diseases that are difficult to control\n* Severe hepatic and renal dysfunction\n* Abnormal coagulation\n* The presence of other serious physical or mental illness or laboratory abnormalities may increase the risk of participating in the study, or interfere with the results of the study, as well as the patients who the investigator believes are not suitable for participating in the study",{"count":453,"type":20},200,[55,306],"Patients with stage cT3-4N+M0 gastric cancer were recommended to receive neoadjuvant chemotherapy before radical surgery in terms of the eradication of micrometastasis in addition to local control, higher compliance with intensive chemotherapy, and avoidance of futile surgery by detection of initially invisible distant metastasis after rapid disease progression. However, in some studies, gastrectomy followed by neoadjuvant chemotherapy failed to demonstrate survival benefits for these patients. And peritoneal recurrence was the most common and devastating reason. Hyperthermic intraperitoneal chemotherapy (HIPEC) was introduced for peritoneal cancer last century. A few studies suggested HIPEC could improve prognosis in patients with limited peritoneal metastasis from various cancer. In summary, we conducted this study to confirm the efficacy and safety of HIPEC after gastrectomy in patients with advanced gastric cancer received neoadjuvant chemotherapy.",[229,28],"2022-12-04",{"date":459,"type":35},"2022-12-06",{"date":439,"type":20},{"date":441,"type":20},{"name":463,"class":42},"Zhixin Cao",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":43},"100307303","phase-2-adjuvant-pressurized-intraperitoneal-aerosol-chemotherapy-pipac-in-resected-high-risk-colon-cancer-patients-100307303","NCT03280511","Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients","Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients - The PIPAC-OPC3 CC Trial","Inclusion Criteria:\n\n* Radically resected colon cancer patients with adeno- or signet ring cell carcinomas with high-risk tumors defined as: perforated \u002F pT4NanyM0 (UICC 8th edition) \u002F pTanyNanyM1 with radically resected PM including ovarian metastases\n* Performance status 0-1\n* Fertile women must use approved contraceptives (see below)\n* Age \\> 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Radiologically or clinically proven relapse.\n* Previous cytoreductive surgery (CRS) with HIPEC\n* Other malignant diagnosis within the last 2 years\n* Contraindications to laparoscopy (e.g. severe adhesions, peritonitis)\n* A history of allergic reaction to oxaliplatin or other platinum containing compounds\n* Renal impairment, defined as GFR \\\u003C 50 ml\u002Fmin, (Cockcroft-Gault Equation).\n* Myocardial insufficiency, defined as NYHA class \\> 2.\n* Impaired liver function defined as bilirubin ≥ 1.5 x UNL (upper normal limit).\n* Inadequate haematological function defined as ANC ≤ 1.5 x 109\u002Fl and platelets ≤ 100 x 109\u002Fl.\n* Any other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.",{"count":84,"type":20},[55],"In this study, patients will be offered two Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatments with oxaliplatin after primary resection and standard adjuvant chemotherapy (if indicated) for colon cancer. Furthermore, the study will explore, whether it is possible to find free intraperitoneal tumor cells (FITC) after resection and adjuvant chemotherapy for colon cancer.",[475,58,28,476],"Peritoneum Cancer","Colo-rectal Cancer","2022-10-05",{"date":479,"type":35},"2022-10-06",{"date":481,"type":35},"2017-12-14",{"date":483,"type":20},"2027-03-01",{"name":485,"class":42},"Michael Bau Mortensen",{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":372,"enrollmentInfo":493,"targetDuration":4,"studyType":21,"phases":495,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100446594","phase-2-hipec-as-in-patients-with-peritoneal-metastasis-of-the-stomach-or-esophagogastric-junction-100446594","NCT05095467","HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction","Prospective Study With HIPEC-AS in Patients With Locally Advanced, Limited or Extensive Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 75 years old;\n2. The primary gastric lesion was diagnosed as gastric or esophagogastric junction adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, and poorly differentiated adenocarcinoma. )\n3. The tumor is located in the stomach or esophagogastric junction (Siewert type II\u002FIII)\n4. The preoperative clinical staging is cT4aNxM0, P0 or cTxNxM1\\*, P1 (\\*no other distant metastases except peritoneal metastasis)\n5. Good bone marrow reserve function: HB≥90g\u002FL; ANC ≥1.5×10\\*9\u002FL; PLT ≥80×10\\*9\u002FL\n6. Good liver and kidney function reserve: BIL ≤ 1.5 times the upper limit of normal (ULN); ALT and AST ≤ 2.5×ULN; Crea≤1×ULN;\n7. Good coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN, activated partial thromboplastin time (APTT) ≤ 1.5 times ULN\n8. ECOG (Eastern Cooperative Oncology Group) physical status score 0-2;\n9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc;\n10. Written informed consent.\n\nExclusion Criteria:\n\n1. There are distant metastases other than peritoneal metastases;\n2. Complications of gastric cancer require emergency treatment, such as bleeding, perforation, obstruction, etc.;\n3. Suffer from other malignant tumors within five years;\n4. Body temperature ≥38℃ or complicated with infectious diseases requiring systemic treatment;\n5. If there is a history of uncontrolled epilepsy, central nervous system disease, or mental disorder, the investigator will determine whether the clinical severity hinders the signing of informed consent or affects the patient's compliance with oral medications;\n6. Clinically serious (ie active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring drug intervention, or recent history of myocardial infarction within 12 months;\n7. Severe respiratory diseases;\n8. Severe liver and kidney dysfunction;\n9. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome, which may affect the absorption of oral drugs;\n10. Diseases such as severe diabetes, hyperthyroidism and hypothyroidism have not been clinically controlled.\n11. Those who continue to use glucocorticoid therapy within 1 month (except for local application) or who require immunosuppressive therapy for organ transplantation;\n12. Pregnant or lactating women;\n13. The patient has participated or is participating in other clinical studies (within 6 months);",{"count":494,"type":20},157,[55],"HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include \"cT4aNxM0, P0 or cTxNxM1, P1\" patients with gastric or esophagogastric junction adenocarcinoma, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC combined with AS in the perioperative period. Patients enrolled will be divided into three groups. Among them, group A is the patients with locally resectable GC; group B is patients with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis stage P1c. The primary purpose is to evaluate the 3-year overall survival rate.",[498,28],"Stomach Neoplasms",[498,28,500,501],"Hyperthermic Intraperitoneal Chemotherapy","paclitaxel","2021-10-26",{"date":504,"type":35},"2021-10-27",{"date":506,"type":20},"2021-10",{"date":508,"type":20},"2026-10",{"name":510,"class":42},"Xuefei.Wang"]